145 related articles for article (PubMed ID: 38371040)
41. Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report.
Kai Y; Matsuda M; Suzuki K; Kasamatsu T; Kajita A; Uno K; Muro S
Cureus; 2022 Mar; 14(3):e23411. PubMed ID: 35481309
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
43. Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies.
Shimizu A; Shirai I; Ogawa K; Miura A; Haruhara K; Oshiro K; Hamaguchi A; Yokote S; Okabe M; Ueda H; Tsuboi N; Ikeda M; Yokoo T
Intern Med; 2022 Dec; 61(24):3703-3708. PubMed ID: 36171121
[TBL] [Abstract][Full Text] [Related]
44. Comparison of COVID-19 pneumonia during the SARS-CoV-2 Omicron wave and the previous non-Omicron wave in a single facility.
Ito N; Kitahara Y; Miwata K; Okimoto M; Takafuta T
Respir Investig; 2022 Nov; 60(6):772-778. PubMed ID: 36050273
[TBL] [Abstract][Full Text] [Related]
45. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
46. Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience.
Moriello NS; Buonomo AR; Scotto R; Pinchera B; Sarno M; Fusco L; Viceconte G; Iuliano A; Zappulo E; Foggia M; Villari R; Gentile I
Heliyon; 2023 Feb; 9(2):e13126. PubMed ID: 36713627
[TBL] [Abstract][Full Text] [Related]
47. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
48. Case Report: The Experience of Managing a Moderate ARDS Caused by SARS-CoV-2 Omicron BA.2 Variant in Chongqing, China: Can We Do Better?
Peng J; Li Q; Dong J; Yuan G; Wang D
Front Med (Lausanne); 2022; 9():921135. PubMed ID: 35755038
[TBL] [Abstract][Full Text] [Related]
49. Enterovirus-Human-Rhinovirus Infection Leading to Acute Respiratory Distress Syndrome: A Case Report.
Cecchini A; Othman A; Kaur K; Richardson A; Cecchini A
Cureus; 2022 Nov; 14(11):e31615. PubMed ID: 36540479
[TBL] [Abstract][Full Text] [Related]
50. Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy.
Nagai H; Saito M; Adachi E; Sakai-Tagawa Y; Yamayoshi S; Kiso M; Kawamata T; Koga M; Kawaoka Y; Tsutsumi T; Yotsuyanagi H
Jpn J Infect Dis; 2022 Nov; 75(6):608-611. PubMed ID: 35768273
[TBL] [Abstract][Full Text] [Related]
51. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
[TBL] [Abstract][Full Text] [Related]
52. Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS-CoV-2 variants.
Ali KM; Rashid PMA; Ali AM; Tofiq AM; Salih GF; Dana OI; Rostam HM
Eur J Clin Invest; 2023 Sep; 53(9):e14004. PubMed ID: 37036255
[TBL] [Abstract][Full Text] [Related]
53. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.
Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit J; Xavier Gómez-Olivé F; Dawood FS; Mkhencele T; Sun K; Viboud C; ; Tempia S
medRxiv; 2021 Dec; ():. PubMed ID: 34909794
[TBL] [Abstract][Full Text] [Related]
54. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
55. Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.
Hettle D; Hutchings S; Muir P; Moran E;
Clin Infect Pract; 2022 Nov; 16():100210. PubMed ID: 36405361
[TBL] [Abstract][Full Text] [Related]
56. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
57. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P
Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
[TBL] [Abstract][Full Text] [Related]
59. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
Ali S; Khalid S; Afridi M; Akhtar S; Khader YS; Akhtar H
JMIR Public Health Surveill; 2021 May; 7(5):e27609. PubMed ID: 34009133
[TBL] [Abstract][Full Text] [Related]
60. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
